Richard Marshall, Juvenescence CEO
UK biotech Juvenescence targets $150M+ for 'healthy lifespan' drug candidates
The “healthy lifespan” space is attracting more dollars.
Juvenescence is out with a $76 million Series B-1, its first equity funding since before the Covid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
